<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">22369198</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>07</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-4804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>55</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Mar</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medicinal chemistry</Title>
                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2574-84</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1021/jm2016057</ELocationID>
            <Abstract>
                <AbstractText>The bradykinin (BK) B1 receptor is an attractive target for the treatment of chronic pain and inflammation. Starting from a dual B1 and B2 antagonist, novel antagonists were designed that display low-nanomolar affinity for human B1 receptor and selectivity over B2. Initially, potent imidazoline derivatives were studied, but these compounds suffered from low bioavailability. This issue could be overcome by the use of less basic amino derivatives leading to orally active compounds.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Barth</LastName>
                    <ForeName>Martine</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemical Design and Synthesis, Clinical Candidate Selection, Laboratoires Fournier, 50 Rue de Dijon, 21121 Daix, France. martine.barth@abbott.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bondoux</LastName>
                    <ForeName>Michel</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luccarini</LastName>
                    <ForeName>Jean-Michel</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peyrou</LastName>
                    <ForeName>Vincent</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dodey</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pruneau</LastName>
                    <ForeName>Didier</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Massardier</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paquet</LastName>
                    <ForeName>Jean-Luc</ForeName>
                    <Initials>JL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>03</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Med Chem</MedlineTA>
            <NlmUniqueID>9716531</NlmUniqueID>
            <ISSNLinking>0022-2623</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D065169">Bradykinin B1 Receptor Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D065094">Bradykinin B2 Receptor Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D048288">Imidazolines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065169" MajorTopicYN="Y">Bradykinin B1 Receptor Antagonists</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065094" MajorTopicYN="Y">Bradykinin B2 Receptor Antagonists</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002522" MajorTopicYN="N">Cercopithecus aethiops</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006930" MajorTopicYN="N">Hyperalgesia</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048288" MajorTopicYN="N">Imidazolines</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>7</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22369198</ArticleId>
            <ArticleId IdType="doi">10.1021/jm2016057</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>